Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MG-EVOLUTION. Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis: A Real-World Study With Biomarker Analysis

NCT06967480 is registered in ClinicalTrials.gov with Alexion Pharmaceuticals, Inc. as lead sponsor.

NCT NCT06967480
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06967480 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MG-EVOLUTION. Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis: A Real-World Study With Biomarker Analysis
Lead sponsor
Alexion Pharmaceuticals, Inc.
Phase
Observational
Overall status
Recruiting
Start date
July 31, 2025
Completion date
June 30, 2027
Enrollment
40 (estimated)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

anti-achr antibody positive, generalized myasthenia gravis